Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06067828 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 171
- Enrollment target
NCT06067828 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 171 participants.
The verdict
NCT06067828, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 171 participants
- Enrollment target
Study Summary
This study will investigate the effect of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) compared with Placebo MDI, and Budesonide and Formoterol Fumarate (BFF) MDI on isotime inspiratory capacity (IC) and exercise endurance time.
Interventions
- DRUG Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate
- DRUG Treatment B: Budesonide and Formoterol Fumarate
- DRUG Treatment C : Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2023-10-24 |
| Est. Completion | 2026-01-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06067828
The ClinicalTrials.gov registry entry for NCT06067828 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate is the first listed.
NCT06067828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06067828 about?
NCT06067828 is a clinical study titled "A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).". This study will investigate the effect of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) compared with Placebo MDI, and Budesonide and Formoterol Fumarate (BFF) MDI on isotime inspiratory capacity (IC) and exercise endurance time.
What is the current status of trial NCT06067828?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 171 participants. The study started on 2023-10-24. Estimated completion is 2026-01-22.
What interventions are being tested in trial NCT06067828?
The interventions under investigation include: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate (DRUG), Treatment B: Budesonide and Formoterol Fumarate (DRUG), Treatment C : Placebo (DRUG).
Who is sponsoring clinical trial NCT06067828?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.